← All Myriad Genetics INC filings

Myriad Genetics INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
MYGN
Myriad Genetics INC
10-K: Myriad Genetics Reports $365.9M Loss Amid Revenue Dip
Myriad Genetics reported a significant net loss of $365.9 million in 2025, driven by substantial impairment charges and a 2% revenue decrease, despite strategic advancements in its testing portfolio.
NASDAQ
MYGN
Myriad Genetics INC
10-K: Myriad Genetics Reports FY2024 Results, Navigates Reimbursement Challenges
Myriad Genetics announces its FY2024 financial results, highlighting revenue growth across key segments while addressing challenges related to reimbursement coverage.
NASDAQ
MYGN
Myriad Genetics INC
10-K: Myriad Genetics Inks 15-Year Lease for New Salt Lake City Facility, Secures Expansion Options
Myriad Genetics has entered into a 15-year lease agreement for a new facility in Salt Lake City, with options for expansion and early termination under specific conditions.